Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infections

Zhen, Sisi; Wang, Hui; Feng, Sizhou

doi:10.1007/s15010-022-01876-x

Cited by 20 publications

(14 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the bacteria are eliminated, the number of macrophages was reduced to avoid an overactive inflammatory response. [ 37–39 ] Cef and Euc did not increase macrophage aggregation in the bladder (Figure S1, Supporting Information). In comparison to the Con group, the expression of CD68 was significantly elevated in the Model group (Figure 5E,F), which was reversed in the treated groups.…”

Section: Resultsmentioning

confidence: 96%

A Versatile Nanoemulsion of Antibiotic and Eucalyptol with Synergistic Effects Against E. Coli Infected Urocystitis

Guo,

Lan,

Qian

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

The extensive use and misuse of antibiotics have resulted in bacterial resistance becoming increasing commonplace. Essential oils (EOs) are known to possess antimicrobial properties and therefore have many potential practical applications. However, the default of hydrophobicity, chemical instability, and volatility limit scope of application. Encapsulation of EOs in colloidal delivery systems can mitigate these challenges and allow for greater efficacy. A homogenous nanoemulsion (HS15‐CE) containing a combination of eucalyptol (Euc) and cefradine (Cef) is developed to explore its synergistic effect on antibacterial activity and potentially reduce the amount of antibiotic required to treat bacterial infections. The HS15‐CE nanoemulsion displays a synergistic effect on the inhibition of Escherichia coli (E. coli) growth in vitro, significantly decreasing the minimum inhibitory concentration (MIC) by eight times. The ex vivo imaging reveals high accumulation concentrations and long retention in bladders. Moreover, the nanoemulsion alleviates the E. coli induced cystitis infection, as evidenced by decreased bacterial colonies in urine, reduced inflammatory cytokines, and increased expression of tight junctional protein ZO‐1. These findings suggest the potential of the HS15‐CE nanoemulsion in providing a synergistic effect for the treatment of bacterial urocystitis.

show abstract

Section: Resultsmentioning

confidence: 96%

A Versatile Nanoemulsion of Antibiotic and Eucalyptol with Synergistic Effects Against E. Coli Infected Urocystitis

Guo,

Lan,

Qian

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…Approved by the National Drug Administration (CFDA) on May 21, 2019, for the treatment of complex intraperitoneal infections (cIAI), hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP), caused by Klebsiella pneumoniae (K. pneumoniae), Enterobacter cloacae, Escherichia coli (E. coli), Proteus mirabilis and Pseudomonas aeruginosa (P. aeruginosa) , aged ≥18 years. CAZ-AVI can combat infections caused by most MDR-E strains, including carbapenem-resistant Enterobacteriaceae (CRE) ( Zhen and Feng, 2021 ). CAZ-AVI) is composed of the third-generation cephalosporin ceftazidime with the novel non-β-lactamase β-lactamase inhibitor abvibatam (AVI), which inhibits class A, C, and some class D enzymes.…”

Section: Introductionmentioning

confidence: 99%

Clinical distribution of carbapenem genotypes and resistance to ceftazidime-avibactam in Enterobacteriaceae bacteria

Zhu,

Guo,

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

IntroductionBacterial resistance is a major threat to public health worldwide. To gain an understanding of the clinical infection distribution, drug resistance information, and genotype of CRE in Dongguan, China, as well as the resistance of relevant genotypes to CAZ-AVI, this research aims to improve drug resistance monitoring information in Dongguan and provide a reliable basis for the clinical control and treatment of CRE infection.MethodsVITEK-2 Compact automatic analyzer was utilized to identify 516 strains of CRE collected from January 2017 to June 2023. To determine drug sensitivity, the K-B method, E-test, and MIC methods were used. From June 2022 to June 2023, 80 CRE strains were selected, and GeneXpert Carba-R was used to detect and identify the genotype of the carbapenemase present in the collected CRE strains. An in-depth analysis was conducted on the CAZ-AVI in vitro drug sensitivity activity of various genotypes of CRE, and the results were statistically evaluated using SPSS 23.0 and WHONET 5.6 software.ResultsThis study identified 516 CRE strains, with the majority (70.16%) being K.pneumoniae, followed by E.coli (18.99%). Respiratory specimens had highest detection rate with 53.77% identified, whereas urine specimens had the second highest detection rate with 17.99%. From June 2022 to June 2023, 95% of the strains tested using the CRE GeneXpert Carba-R assay possessed carbapenemase genes, of which 32.5% were blaNDM strains and 61.25% blaKPC strains. The results showed that CRE strains containing blaKPC had a significantly higher rate of resistance to amikacin, cefepime, and aztreonam than those harboring blaNDM.ConclusionsThe CRE strains isolated from Dongguan region demonstrated a high resistance rate to various antibiotics used in clinical practice but a low resistance rate to tigecycline. These strains produce Class A serine carbapenemases and Class B metals β-lactamases, with the majority of them carrying blaNDM and blaKPC. Notably, CRE strains with blaKPC and blaNDM had significantly lower resistance rates to tigecycline. CAZ-AVI showed a good sensitivity rate with no resistance to CRE strains carrying blaKPC. Therefore, CAZ-AVI and tigecycline should be used as a guide for rational use of antibiotics in clinical practice to effectively treat CRE.

show abstract

“…The presence and spread of MDR, XDR and even PDR Gram-negatives is dramatically limiting the treatment options for infections caused by these pathogens, whereas the pipeline of new antimicrobials is slow and novel compounds including tigecycline, eravacycline and cefiderocol do not always meet the expectations [5][6][7]. Current β-lactams combined with novel β-lactamase inhibitors provide some solutions especially against nonmetallo-β-lactamase producers [8], but they are not applicable in all cases, and resistance Antibiotics 2023, 12, 93 2 of 12 has already emerged [9,10]. Monotherapy with formerly abandoned antimicrobials such as fosfomycin and polymyxins is another option.…”

Section: Introductionmentioning

confidence: 99%

In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae

et al. 2023

View full text Add to dashboard Cite

Polymyxins are commonly used as the last resort for the treatment of MDR Acinetobacter baumannii and Klebsiella pneumoniae nosocomial infections; however, apart from the already known toxicity issues, resistance to these agents is emerging. In the present study, we assessed the in vitro synergistic activity of antimicrobial combinations against carbapenem-resistant and colistin-resistant A. baumannii and K. pneumoniae in an effort to provide more options for their treatment. Two hundred A. baumannii and one hundred and six K. pneumoniae single clinical isolates with resistance to carbapenems and colistin, recovered between 1 January 2021 and 31 July 2022,were included. A. baumannii were tested by the MIC test strip fixed-ratio method for combinations of colistin with either meropenem or rifampicin or daptomycin. K. pneumoniae were tested for the combinations of colistin with meropenem and ceftazidime/avibactam with aztreonam. Synergy was observed at: 98.99% for colistin and meropenem against A. baumannii; 91.52% for colistin and rifampicin; and 100% for colistin and daptomycin. Synergy was also observed at: 73.56% for colistin and meropenem against K. pneumoniae and; and 93% for ceftazidime/avibactam with aztreonam. The tested antimicrobial combinations presented high synergy rates, rendering them valuable options against A. baumannii and K. pneumoniae infections.

show abstract

Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infections

Cited by 20 publications

References 115 publications

A Versatile Nanoemulsion of Antibiotic and Eucalyptol with Synergistic Effects Against E. Coli Infected Urocystitis

A Versatile Nanoemulsion of Antibiotic and Eucalyptol with Synergistic Effects Against E. Coli Infected Urocystitis

Clinical distribution of carbapenem genotypes and resistance to ceftazidime-avibactam in Enterobacteriaceae bacteria

In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae

Contact Info

Product

Resources

About